ClinicalThought
View More
Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education.
Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.
In this episode, Ignacio Durán, MD, PhD, and Alison Birtle, MD, FRCP, FRCR, discuss toxicities associated with FGFR inhibitors used in the treatment of urothelial cancer and other malignancies.
Presenters:
Ignacio Durán, MD, PhD
Associate Professor
GU Oncology Program Leader
Department of Medical Oncology
Hospital Universitario Marques de Valdecilla-Idival
Santander, Spain
Alison Birtle, MD, FRCP, FRCR
Honorary Senior Lecturer
Faculty of Health and Medicine
University of Manchester
Manchester, United Kingdom
Consultant Oncologist
Rosemere Cancer Centre
Lancashire Teaching Hospitals
Preston, Lancashire, United Kingdom
Contact Clinical Care Options
For customer support please email: customersupport@cealliance.com
Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191
Commentary from Nelson F. Sanchez, MD, on caring for transgender individuals, from the healthcare disparities they face to how healthcare professionals can improve their care, from Clinical Care Options (CCO)
Nelson F. Sanchez, MD
Downloadable slideset from Eric Jonasch, MD on managing treatment-related adverse events for patients with RCC, from Clinical Care Options (CCO).
Eric Jonasch, MD
Released: June 5, 2022
Downloadable slideset from Katy E. Beckermann, MD, PhD on the selection and sequencing of therapy for patients with advanced RCC after progression on first-line therapy, from Clinical Care Options (CCO).
Katy E. Beckermann, MD, PhD
Released: June 5, 2022
Downloadable slideset from Naomi B. Haas, MD on adjuvant approaches and first line treatment options for patients with RCC, from Clinical Care Options (CCO).
Naomi B. Haas, MD
Released: June 5, 2022
You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.